326 results on '"Oesterreich S"'
Search Results
302. Oestrogen receptor is a critical component required for insulin-like growth factor (IGF)-mediated signalling and growth in MCF-7 cells
- Author
-
Lee AV, Guler BL, Sun X, Oesterreich S, Zhang QP, Curran EM, and Welshons WV
- Published
- 2000
- Full Text
- View/download PDF
303. HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer.
- Author
-
Townson SM, Sullivan T, Zhang Q, Clark GM, Osborne CK, Lee AV, and Oesterreich S
- Subjects
- 3T3 Cells metabolism, Animals, Breast Neoplasms metabolism, CHO Cells metabolism, Cell Division physiology, Cell Nucleus physiology, Cricetinae, DNA-Binding Proteins biosynthesis, DNA-Binding Proteins genetics, Gene Expression, Green Fluorescent Proteins, Humans, Luminescent Proteins biosynthesis, Luminescent Proteins genetics, Mice, Nuclear Proteins biosynthesis, Nuclear Proteins genetics, Recombinant Fusion Proteins biosynthesis, Recombinant Fusion Proteins genetics, Transfection, Tumor Cells, Cultured, Aneuploidy, Breast Neoplasms genetics, Breast Neoplasms pathology, DNA-Binding Proteins physiology, Matrix Attachment Region Binding Proteins, Nuclear Matrix-Associated Proteins, Nuclear Proteins physiology, Receptors, Estrogen
- Abstract
HET/SAF-B was originally cloned as a nuclear matrix protein that bound to matrix attachment regions and as a transcriptional repressor of the small heat shock protein hsp27. In addition, we have found recently that HET/SAF-B is also a corepressor of estrogen receptor activity. Estrogen receptor has a very well-described role in breast cancer, and aberrant expression of nuclear matrix and heat shock proteins has also been implicated in breast tumorigenesis. Therefore, we asked whether HET/SAF-B itself could be important in breast cancer. Toward this goal we examined its expression in breast cancer cell lines and asked whether HET/SAF-B can affect breast cancer cell proliferation. Finally, we studied HET/SAF-B expression in clinical breast cancer samples. HET/SAF-B protein and mRNA were detected at varying levels in all of the eight breast cancer cell lines examined. Using a number of different approaches to modulate the level of HET/SAF-B protein in the cell, we found that HET/SAF-B levels are inversely correlated with cell proliferation. In addition,transfection of HET/SAF-B fused to the green fluorescent protein led to the formation of multinucleated cells not observed in cells transfected with green fluorescent protein alone, suggesting that this effect is a direct result of HET/SAF-B overexpression. Western blot analysis of HET/SAF-B in 61 human breast tumors revealed widely varying levels of HET/SAF-B expression, with some tumors (16%) lacking any detectable HET/SAF-B. Statistical analysis showed that high HET/SAF-B expression in these tumors was associated with low S-phase fraction and with aneuploidy, consistent with our results from transfection experiments in tissue culture cells. We conclude that HET/SAF-B plays an important role in breast cancer, and we discuss possible mechanisms of the involvement of HET/SAF-B in cell proliferation and division.
- Published
- 2000
304. Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation.
- Author
-
Oesterreich S, Zhang Q, Hopp T, Fuqua SA, Michaelis M, Zhao HH, Davie JR, Osborne CK, and Lee AV
- Subjects
- Adenocarcinoma metabolism, Adenocarcinoma pathology, Animals, Base Sequence, Bone Neoplasms pathology, Breast Neoplasms metabolism, Breast Neoplasms pathology, COS Cells, Carcinoma, Hepatocellular pathology, Chlorocebus aethiops, DNA metabolism, Depression, Chemical, Estradiol pharmacology, Estrogen Receptor Modulators metabolism, Female, Humans, Liver Neoplasms pathology, Macromolecular Substances, Molecular Sequence Data, Neoplasm Proteins metabolism, Neoplasms, Hormone-Dependent metabolism, Neoplasms, Hormone-Dependent pathology, Osteosarcoma pathology, Protein Binding, Protein Structure, Tertiary, Receptors, Estrogen drug effects, Recombinant Fusion Proteins metabolism, Structure-Activity Relationship, Tamoxifen metabolism, Tumor Cells, Cultured drug effects, DNA-Binding Proteins metabolism, Estrogen Receptor Modulators pharmacology, Matrix Attachment Region Binding Proteins, Nuclear Matrix-Associated Proteins, Nuclear Proteins metabolism, Receptors, Estrogen metabolism, Tamoxifen pharmacology, Transcriptional Activation drug effects
- Abstract
The estrogen receptor (ER) is a ligand-dependent transcription factor that acts in a cell- and promoter-specific manner. Evidence suggests that the activity of the ER can be regulated by a number of other stimuli (e.g. growth factors) and that the effects of the ER are modulated by nuclear factors termed coregulators. While the interplay among these factors may in part explain the pleiotropic effects elicited by the ER, there are several other less well described mechanisms of control, such as interactions with the nuclear matrix. Here we report that the nuclear matrix protein/scaffold attachment factor HET/SAF-B is an ER-interacting protein. ER and HET/SAF-B interact in in vitro binding assays, with HET binding to both the ER DNA-binding domain and the hinge region. Coimmunoprecipitation experiments reveal that HET/SAF-B and ER associate in cell lines in the presence or absence of estradiol, but binding is increased by the antiestrogen tamoxifen. HET/SAF-B enhances tamoxifen antagonism of estrogen-induced ER-mediated transactivation, but at high concentrations can inhibit both estrogen and tamoxifen-induced ER activity. HET/SAF-B-mediated repression of ER activity is dependent upon interaction with the ER-DBD. While the existence of high-affinity binding sites for the ER in the nuclear matrix has been known for some time, we now provide evidence of a specific nuclear matrix protein binding to the ER. Furthermore, our data showing that HET/SAF-B binds to ER particularly strongly in the presence of tamoxifen suggests that it may be important for the antagonist effect of tamoxifen.
- Published
- 2000
- Full Text
- View/download PDF
305. Insulin-like growth factor I-induced degradation of insulin receptor substrate 1 is mediated by the 26S proteasome and blocked by phosphatidylinositol 3'-kinase inhibition.
- Author
-
Lee AV, Gooch JL, Oesterreich S, Guler RL, and Yee D
- Subjects
- Animals, Cell Line, Enzyme Inhibitors pharmacology, Insulin Receptor Substrate Proteins, Phosphoinositide-3 Kinase Inhibitors, Phosphorylation, Insulin-Like Growth Factor I metabolism, Peptide Hydrolases metabolism, Phosphatidylinositol 3-Kinases metabolism, Phosphoproteins metabolism, Proteasome Endopeptidase Complex, Signal Transduction drug effects
- Abstract
Insulin receptor substrate 1 (IRS-1) is a critical adapter protein involved in both insulin and insulin-like growth factor (IGF) signaling. Due to the fact that alteration of IRS-1 levels can affect the sensitivity and response to both insulin and IGF-I, we examined the ability of each of these ligands to affect IRS-1 expression. IGF-I (10 nM) stimulation of MCF-7 breast cancer cells caused a transient tyrosine phosphorylation of IRS-1 that was maximal at 15 min and decreased thereafter. The decrease in tyrosine phosphorylation of IRS-1 was paralleled by an apparent decrease in IRS-1 levels. The IGF-mediated decrease in IRS-1 expression was posttranscriptional and due to a decrease in the half-life of the IRS-1 protein. Insulin (10 nM) caused tyrosine phosphorylation of IRS-1 but not degradation, whereas high concentrations of insulin (10 microM) resulted in degradation of IRS-1. IGF-I (10 nM) stimulation resulted in transient IRS-1 phosphorylation and extracellular signal-related kinase (ERK) activation. In contrast, insulin (10 nM) caused sustained IRS-1 phosphorylation and ERK activation. Inhibition of 26S proteasome activity by the use of lactacystin or MG132 completely blocked IGF-mediated degradation of IRS-1. Furthermore, coimmunoprecipitation experiments showed an association between ubiquitin and IRS-1 that was increased by treatment of cells with IGF-I. Finally, IGF-mediated degradation of IRS-1 was blocked by inhibition of phosphatidylinositol 3'-kinase activity but was not affected by inhibition of ERK, suggesting that this may represent a direct negative-feedback mechanism resulting from downstream IRS-1 signaling. We conclude that IGF-I can cause ligand-mediated degradation of IRS-1 via the ubiquitin-mediated 26S proteasome and a phosphatidylinositol 3'-kinase-dependent mechanism and that control of degradation may have profound effects on downstream activation of signaling pathways.
- Published
- 2000
- Full Text
- View/download PDF
306. Tumor suppressor genes in breast cancer.
- Author
-
Oesterreich S and Fuqua SA
- Subjects
- Animals, Breast Neoplasms epidemiology, Female, Genes, Retinoblastoma, Genes, p53, Humans, Incidence, Breast Neoplasms genetics, Genes, Tumor Suppressor
- Published
- 1999
- Full Text
- View/download PDF
307. Low cell motility induced by hsp27 overexpression decreases osteolytic bone metastases of human breast cancer cells in vivo.
- Author
-
Lemieux P, Harvey J, Guise T, Dallas M, Oesterreich S, Yin Jj, Selander K, and Fuqua S
- Subjects
- Animals, Female, HSP27 Heat-Shock Proteins, Humans, Mice, Molecular Chaperones, Parathyroid Hormone-Related Protein, Proteins metabolism, Tumor Cells, Cultured, Bone Neoplasms secondary, Breast Neoplasms pathology, Cell Movement, Heat-Shock Proteins, Neoplasm Proteins biosynthesis, Osteolysis
- Abstract
The mechanisms controlling the formation of osteolytic bone metastases in patients with breast cancer are still poorly understood. To explore the role of motility in the establishment of osteolytic bone metastases, we have used a model of bone metastasis in which MDA-MB-231 breast cancer cells exhibiting low (hsp27-transfectants) and high (control-transfectant) endogenous cell motility were compared. We found that MDA-MB-231 cells exhibiting low cell motility were less capable of establishing osteolytic lesions. The number and the area of the osteolytic lesions in mice inoculated with low motility cells were both significantly smaller. Histomorphometry of bone lesions also demonstrated less tumor area in mice bearing hsp27 transfectants although there was no difference in the osteoclast number per square millimeter of tumor-bone interface. These data suggest that cell motility may be an important mechanism in the metastatic cascade of breast cancer cells to the bone and that controlling cell motility may be a useful target to prevent the establishment of osteolytic bone metastases.
- Published
- 1999
- Full Text
- View/download PDF
308. Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells.
- Author
-
Hansen RK, Parra I, Lemieux P, Oesterreich S, Hilsenbeck SG, and Fuqua SA
- Subjects
- Antigens, Neoplasm, Breast Neoplasms enzymology, Breast Neoplasms genetics, Clone Cells, DNA Fragmentation, DNA-Binding Proteins, HSP27 Heat-Shock Proteins, Humans, Isoenzymes antagonists & inhibitors, Isoenzymes biosynthesis, Molecular Chaperones, Neoplasm Proteins genetics, Neoplasm Proteins physiology, Proto-Oncogene Proteins c-bcl-2 biosynthesis, Topoisomerase II Inhibitors, Transfection, Tumor Cells, Cultured drug effects, Antineoplastic Agents antagonists & inhibitors, Antineoplastic Agents pharmacology, Apoptosis drug effects, Breast Neoplasms metabolism, Breast Neoplasms pathology, DNA Topoisomerases, Type II biosynthesis, Doxorubicin antagonists & inhibitors, Doxorubicin pharmacology, Heat-Shock Proteins, Neoplasm Proteins biosynthesis
- Abstract
Previously we demonstrated that heat shock protein 27 (hsp27) overexpression confers resistance to the chemotherapeutic agent doxorubicin in MDA-MB-231 breast cancer cells. Since induction of apoptosis is one underlying mechanism of chemotherapeutic drug action, we investigated the effect of hsp27 overexpression on doxorubicin-induced apoptosis, finding that hsp27 protects MDA-MB-231 cells from apoptosis. We also examined expression of the doxorubicin target, topoisomerase II (topo II), in control and hsp27-overexpressing stable transfectants, as topo II expression is important for both drug sensitivity and the initiation of apoptosis by doxorubicin. The relative levels of both topo IIalpha and beta were higher in the controls than the hsp27-overexpressing clones, suggesting that the apoptotic protective effect of hsp27 overexpression in MDA-MB-231 cells is associated with altered topo II expression.
- Published
- 1999
- Full Text
- View/download PDF
309. In situ cross-linking by cisplatin of nuclear matrix-bound transcription factors to nuclear DNA of human breast cancer cells.
- Author
-
Samuel SK, Spencer VA, Bajno L, Sun JM, Holth LT, Oesterreich S, and Davie JR
- Subjects
- Antigens, Nuclear, Breast Neoplasms metabolism, Cisplatin metabolism, DNA Adducts metabolism, DNA, Neoplasm metabolism, Humans, Nuclear Proteins metabolism, Transcription Factors drug effects, Transcription Factors metabolism, Tumor Cells, Cultured drug effects, Antineoplastic Agents pharmacology, Cisplatin pharmacology, DNA, Neoplasm drug effects, Nuclear Proteins drug effects
- Abstract
Cisplatin is an antitumor drug that is used to treat several types of cancers. In this study, we analyzed the proteins that were cross-linked to DNA in situ in MCF-7 human breast cancer cells incubated with cisplatin. We show that cisplatin cross-links nuclear matrix proteins to DNA. In immunoblotting experiments, we found that nuclear matrix-associated transcription factors and cofactors (estrogen receptor, HET/SAF-B, hnRNP K, and histone deacetylase 1) were cross-linked to nuclear DNA. These transcription factors and cofactors have essential roles in the regulation of genes involved in the proliferation of breast cancer cells and in the organization and structure of chromatin. We applied a novel protocol to demonstrate that the nuclear matrix-bound transcription factors/cofactors were cross-linked to DNA fragments attached to the nuclear matrix. These results suggest that the cross-linking of nuclear matrix-associated transcription factors and cofactors to DNA may be one of the mechanisms by which cisplatin inhibits transcription and replication processes.
- Published
- 1998
310. Induction of heat shock protein 27 by hydroxyurea and its relationship to experimental metastasis.
- Author
-
Eskenazi AE, Powers J, Pinkas J, Oesterreich S, Fuqua SA, and Frantz CN
- Subjects
- Animals, Female, Gene Expression Regulation, Neoplastic drug effects, Heat Stress Disorders metabolism, Humans, Melanoma metabolism, Mice, Mice, Inbred C57BL, RNA, Messenger genetics, RNA, Neoplasm genetics, Recombinant Proteins, Transfection, Tumor Cells, Cultured, Heat-Shock Proteins biosynthesis, Hydroxyurea pharmacology, Melanoma pathology, Neoplasm Metastasis
- Abstract
Treatment of tumor cells with hydroxyurea (HU) has been shown to increase the experimental metastatic potential of these cells. We have previously described the induction of stress proteins (antioxidants) by HU in B16 murine melanoma cells and their relationship to the metastatic process. We have now investigated the induction by HU of another set of stress proteins, the heat shock proteins, and their role in experimental metastasis. HU markedly increased the cellular content of heat shock protein (hsp) 27 but not of hsp 90, 72/73, or 60 as measured by immunoblotting. The induction of hsp27 protein was preceded by a specific increase in hsp27 mRNA. Furthermore, HU-treated cells were more thermotolerant. To investigate the functional role of hsp27, human hsp27 cDNA was constitutively overexpressed in B16 cells at levels seen in HU-treated cells. In separate experiments, we induced a global increase in hsps by heat shock. Neither the hsp27 transfectants nor the heat-shocked cells demonstrated an increase in their experimental metastatic capacity. We conclude that hsp27 protein is increased by HU by the specific induction of hsp27 mRNA in B16 melanoma cells but increased hsp27 protein is not responsible for the increase in experimental metastasis. Since high levels of hsp27 are associated with metastatic disease in breast and ovarian cancers, but not in our experimental system, the functional role of hsp27 in metastasis requires further study.
- Published
- 1998
- Full Text
- View/download PDF
311. Novel nuclear matrix protein HET binds to and influences activity of the HSP27 promoter in human breast cancer cells.
- Author
-
Oesterreich S, Lee AV, Sullivan TM, Samuel SK, Davie JR, and Fuqua SA
- Subjects
- Cloning, Molecular, DNA metabolism, DNA-Binding Proteins genetics, DNA-Binding Proteins pharmacology, Glutathione Transferase genetics, Humans, Nuclear Proteins genetics, Nuclear Proteins pharmacology, Recombinant Fusion Proteins, Transfection, Tumor Cells, Cultured, Breast Neoplasms genetics, DNA-Binding Proteins metabolism, Heat-Shock Proteins genetics, Matrix Attachment Region Binding Proteins, Nuclear Matrix chemistry, Nuclear Matrix-Associated Proteins, Nuclear Proteins metabolism, Promoter Regions, Genetic, Receptors, Estrogen
- Abstract
Since the small heat shock protein hsp27 enhances both growth and drug resistance in breast cancer cells, and is a bad prognostic factor in certain subsets of breast cancer patients, we have characterized the transcriptional regulation of hsp27, with the long-term goal of targeting its expression clinically. The majority of the promoter activity resides in the most proximal 200 bp. This region contains an imperfect estrogen response element (ERE) that is separated by a 13-bp spacer that contains a TATA box. Gel-shift analysis revealed the binding of a protein (termed HET for Hsp27-ERE-TATA-binding protein) to this region that was neither the estrogen receptor nor TATA-binding protein. We cloned a complete cDNA (2.9 kb) for HET from an MCF-7 cDNA library. To confirm the identity of the HET clone, we expressed a partial HET clone as a glutathione S-transferase fusion protein, and showed binding to the hsp27 promoter fragment in gel-retardation assays. The HET clone is almost identical to a recently published scaffold attachment factor (SAF-B) cloned from a HeLa cell cDNA library. Scaffold attachment factors are a subset of nuclear matrix proteins (NMP) that interact with matrix attachment regions. Analyzing how HET could act as a regulator of hsp27 transcription and as a SAF/NMP, we studied its subnuclear localization and its effect on hsp27 transcription in human breast cancer cells. We were able to show that HET is localized in the nuclear matrix in various breast cancer cell lines. Furthermore, in transient transfection assays using hsp27 promoter-luciferase reporter constructs, HET overexpression resulted in a dose-dependent decrease of hsp27 promoter activity in several cell lines.
- Published
- 1997
312. Quercetin inhibits heat shock protein induction but not heat shock factor DNA-binding in human breast carcinoma cells.
- Author
-
Hansen RK, Oesterreich S, Lemieux P, Sarge KD, and Fuqua SA
- Subjects
- Binding Sites genetics, Breast Neoplasms genetics, Carcinoma genetics, DNA-Binding Proteins drug effects, DNA-Binding Proteins genetics, HSP70 Heat-Shock Proteins biosynthesis, HSP70 Heat-Shock Proteins drug effects, HeLa Cells, Heat Shock Transcription Factors, Heat-Shock Proteins genetics, Humans, Transcription Factors biosynthesis, Tumor Cells, Cultured, Breast Neoplasms metabolism, Carcinoma metabolism, DNA-Binding Proteins metabolism, Heat-Shock Proteins antagonists & inhibitors, Heat-Shock Proteins biosynthesis, Quercetin pharmacology
- Abstract
The flavonoid quercetin inhibits the heat-induced synthesis of heat shock proteins (hsps) in a variety of cell lines. To determine whether quercetin could inhibit hsp expression in breast cancer cells, we used the human breast cancer cell line, MDA-MB-231. Treatment of these cells with quercetin decreased the heat-induced synthesis of hsp27 and hsp70. However, inhibition of hsp expression did not correspond with the reduced ability of heat shock transcription factors (HSFs) to bind DNA. Furthermore, while quercetin treatment inhibited HSF2 expression, it only slightly affected HSF1 expression in breast cancer cells. In contrast, quercetin inhibited both HSF DNA-binding activity and HSF expression in HeLa cells. Our studies suggest that quercetin's action is cell-type specific, and in breast cancer cells may involve regulation of HSF transcriptional activity, rather than regulation of its DNA-binding activity.
- Published
- 1997
- Full Text
- View/download PDF
313. Auto-regulation of the estrogen receptor promoter.
- Author
-
Castles CG, Oesterreich S, Hansen R, and Fuqua SA
- Subjects
- Autocrine Communication, HeLa Cells, Humans, Transfection, Gene Expression Regulation, Promoter Regions, Genetic genetics, Receptors, Estrogen genetics
- Abstract
The presence or absence of estrogen receptor (ER) plays a key role in the diagnosis and treatment of breast tumors. It is known that patients with breast tumors classified as ER-positive have a better prognosis. Observations such as this have led us to explore the question of what makes some breast tumors overexpress ER whereas others express either very low levels or none at all. To begin a study of ER regulation, we first chose to examine a 200 bp region of the ER promoter located immediately upstream from the transcribed sequence of the human ER gene. We found that this region of the ER promoter contained basal activity when transiently transfected into ER-negative HeLa cells. ER promoter activity was further increased by co-transfection of a wild-type ER expression vector, and this increased activity was hormone-dependent. Several ER deletion mutant constructs were also able to increase the activity of the ER promoter fragment, but none could support equivalent activity as was seen with the full-length ER. Therefore, we conclude that the ER can contribute to its own expression, and we hypothesize that this auto-regulation may contribute to its overexpression in some breast tumors.
- Published
- 1997
- Full Text
- View/download PDF
314. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer.
- Author
-
Zhang QX, Borg A, Wolf DM, Oesterreich S, and Fuqua SA
- Subjects
- Breast Neoplasms pathology, Estradiol pharmacology, Female, HeLa Cells, Humans, Models, Genetic, Neoplasm Metastasis, Polymorphism, Single-Stranded Conformational, Receptors, Estrogen agonists, Tamoxifen analogs & derivatives, Tamoxifen pharmacology, Transcription, Genetic, Transfection, Breast Neoplasms genetics, Breast Neoplasms metabolism, Mutation, Receptors, Estrogen genetics, Receptors, Estrogen metabolism
- Abstract
Thirty tumors from metastatic breast cancer patients were screened for mutations in the estrogen receptor (ER) gene using single-strand conformation polymorphism and sequence analysis. Three missense mutations, Ser47Thr, Lys531Glu, and Tyr537Asn, were identified in these lesions. To investigate these mutated ERs or altered transcriptional activation function, expression vectors containing wild-type (wt) and mutant ERs were constructed and cotransfected with different estrogen response element reporter gene constructs into HeLa cells and MDA-MB-231 human breast cancer cells. The first two ER mutants were similar to wt ER. However, the Tyr537Asn ER mutant possessed a potent, estradiol-independent transcriptional activity, as compared to wt ER. Moreover, the constitutive activity of the Tyr537Asn ER mutant was virtually unaffected by estradiol, tamoxifen, or the pure antiestrogen ICI 164,384. Tyr537 is located at the beginning of exon 8 in the COOH-terminal portion of the hormone-binding domain of the ER, to which dimerization and transcription activation functions have also been ascribed. It has been identified as a phosphorylation site implicated in hormone binding, dimerization, and hormone-dependent transcriptional activity. Our results suggest that the Tyr537Asn substitution induces conformational changes in the ER that might mimic hormone binding, not affecting the ability of the receptor to dimerize, but conferring a constitutive transactivation function to the receptor. If present in other metastatic breast tumors, this naturally occurring ER mutant may contribute to breast cancer progression and/or hormone resistance.
- Published
- 1997
315. Assignment of SAFB encoding Hsp27 ERE-TATA binding protein (HET)/scaffold attachment factor B (SAF-B) to human chromosome 19 band p13.
- Author
-
DuPont BR, Garcia DK, Sullivan TM, Naylor SL, and Oesterreich S
- Subjects
- Chromosome Mapping, Humans, Hybrid Cells, In Situ Hybridization, Fluorescence, Promoter Regions, Genetic, TATA Box, Chromosomes, Human, Pair 19, DNA-Binding Proteins genetics, Matrix Attachment Region Binding Proteins, Nuclear Matrix-Associated Proteins, Nuclear Proteins genetics, Receptors, Estrogen
- Published
- 1997
- Full Text
- View/download PDF
316. The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells.
- Author
-
Lemieux P, Oesterreich S, Lawrence JA, Steeg PS, Hilsenbeck SG, Harvey JM, and Fuqua SA
- Subjects
- Animals, Cell Adhesion, Cell Line, Cell Movement, Female, Humans, Lung Neoplasms secondary, Mice, Mice, Inbred BALB C, Neoplasm Transplantation, Transfection, Transplantation, Heterologous, Breast Neoplasms metabolism, Breast Neoplasms pathology, Heat-Shock Proteins physiology, Neoplasm Invasiveness
- Abstract
The small heat shock protein hsp27 is often expressed at high levels in clinical breast tumors; however, its biological role in this disease still remains unclear. Several laboratories have recently shown that hsp27 expression is associated with aggressive tumor behavior. We hypothesized that hsp27 may influence the metastatic tumor process since this is part of tumor 'aggressiveness'. Therefore, we stably transfected breast cancer cell lines with sense (MDA-MB-231) and antisense (MDA-MB-435) hsp27 constructs, respectively, and examined various cellular aspects associated with the metastatic process. We found that hsp27-overexpressing clones lost their protrusive morphology, but exhibited higher membrane ruffling as compared to low expressing cells. hsp27 overexpression also resulted in decreased cell motility, but invasiveness, adhesion, and growth in Matrigel were all significantly increased. Conversely, antisense suppression of hsp27 expression resulted in increased cell motility, but decreased in vitro invasiveness. The direct correlation of hsp27 levels with metastasis was confirmed by an in vivo assay measuring the number of lung metastases in mice injected with hsp27-transfected cells. Thus, we conclude that hsp27 overexpression may influence the invasive and metastatic potential of human breast cancer cells.
- Published
- 1997
317. The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients.
- Author
-
Oesterreich S, Hilsenbeck SG, Ciocca DR, Allred DC, Clark GM, Chamness GC, Osborne CK, and Fuqua SA
- Subjects
- Adult, Aged, Breast Neoplasms mortality, Disease-Free Survival, Female, Humans, Lymphatic Metastasis, Middle Aged, Prognosis, Receptors, Estrogen analysis, Breast Neoplasms chemistry, Heat-Shock Proteins analysis
- Abstract
Heat shock protein 27 (hsp27) belongs to the family of heat shock proteins and is thought to be involved in thermotolerance, cell proliferation, drug resistance, and chaperone processes. The aim of this study was to investigate whether hsp27 levels are correlated with clinical outcome in axillary lymph node-negative breast cancer patients. We describe a Western blot study measuring hsp27 levels in 425 patients and an immunohistochemistry (IHC) study analyzing 788 patients. Results obtained by both methods were concordant. Univariate survival analysis was performed considering hsp27 either as an optimally dichotomized variable or as a continuous variable. Additional data include age at biopsy, tumor size, estrogen receptor (ER) and progesterone receptor status, tumor ploidy and percentage of cells in S phase, and adjuvant therapy. hsp27 levels correlated positively with ER status (P = 0.0001 in Western blot and IHC study), progesterone receptor status (P = 0.0001 in Western blot and IHC study), and aneuploidy (Western blot study, P = 0.0012; IHC study, P = 0.0004) but not with tumor size (Western blot study, P = 0.69; IHC, P = 0.53) or S phase (Western blot study, P = 0.19; IHC study, P = 0.38). Overall, there was no relationship between hsp27 expression and disease-free survival (Western blot study, P = 0.70/0.54; IHC, P = 0.47/0.30) or overall survival (Western blot study, P = 0.16/0.15; IHC, P = 0.46/0.78). Exploratory subset analyses defined by ER status and use of adjuvant treatment indicated that in ER+/untreated patients, high hsp27 levels correlated modestly with shorter disease-free survival (Western blot, P = 0.04/0.04; IHC, P = 0.11/0. 03). hsp27 is not a useful prognostic marker for the clinic in axillary lymph node-negative patients. However, the finding of modest prognostic value of hsp27 in the subgroup of ER+/untreated patients raises new questions about the biological function of hsp27 in breast cancer.
- Published
- 1996
318. Basal regulatory promoter elements of the hsp27 gene in human breast cancer cells.
- Author
-
Oesterreich S, Hickey E, Weber LA, and Fuqua SA
- Subjects
- Base Sequence, Binding Sites, DNA Primers chemistry, DNA-Binding Proteins metabolism, Gene Expression Regulation, Neoplastic, Humans, Molecular Sequence Data, Sequence Deletion, Sp1 Transcription Factor metabolism, Transcription Factor AP-2, Transcription Factors metabolism, Transcription, Genetic, Tumor Cells, Cultured, Heat-Shock Proteins genetics, Promoter Regions, Genetic
- Abstract
The small human heat shock protein hsp27 has been shown to play important roles in diverse cellular processes such as actin polymerization, thermotolerance, growth, and chemotherapeutic drug resistance. Two breast cancer cell lines MCF-7 and MDA-MB-231 were used as a model to study the molecular mechanisms important for basal hsp27 promoter transcriptional activity. A genomic clone containing 1.1 kb of the hsp27 promoter was sequenced and the regulatory elements were characterized. The first 200 bp within this 5'-flanking region holds the majority of the transcriptional activity, according to transient transfection assays using a series of hsp27 promoter deletion fragments in luciferase reporter vectors. The basal activity of this fragment is largely confined to a G/C-rich region containing overlapping SP1 and AP2 transcription factor binding sites.
- Published
- 1996
- Full Text
- View/download PDF
319. Induction of the small stress protein, hsp25, in Ehrlich ascites carcinoma cells by anticancer drugs.
- Author
-
Bielka H, Hoinkis G, Oesterreich S, Stahl J, and Benndorf R
- Subjects
- Animals, Carcinoma, Ehrlich Tumor, HSP27 Heat-Shock Proteins, Molecular Chaperones, Tumor Cells, Cultured, Antineoplastic Agents pharmacology, Heat-Shock Proteins biosynthesis, Neoplasm Proteins biosynthesis
- Abstract
Treatment of in vitro cultured Ehrlich ascites carcinoma cells with cisplatin, daunomycin, doxorubicin, cytosine arabinoside, 3'-fluorodeoxythymidine, colchicine and vincristine in cytostatically effective concentrations results in significantly increased levels of the small stress protein, hsp25, as analyzed by immunoblotting. However, no induction of hsp25 could be detected after treatment of the tumour cells with 5-fluorouracil, aminopterin, amethopterin, mithramycin and cyclophosphamide. None of these cytostatic drugs induces hsp70.
- Published
- 1994
- Full Text
- View/download PDF
320. Heat shock proteins and drug resistance.
- Author
-
Fuqua SA, Oesterreich S, Hilsenbeck SG, Von Hoff DD, Eckardt J, and Osborne CK
- Subjects
- Antineoplastic Agents pharmacology, Breast Neoplasms genetics, Drug Resistance, Gene Expression Regulation, HSP70 Heat-Shock Proteins drug effects, HSP70 Heat-Shock Proteins physiology, Humans, Prognosis, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Heat-Shock Proteins drug effects, Heat-Shock Proteins physiology
- Abstract
Heat shock proteins (hsp's) are induced in cells when exposed to different environmental stressful conditions. We have found that breast cancer cells sometimes express high levels of several hsp's, which may both augment the aggressiveness of these tumors and make them more resistant to treatment. We have shown that hsp70 is an ominous prognostic sign as detected by Western blot assays in node-negative breast tumors, and that hsp27 increases specific resistance to doxorubicin in breast cancer cell lines. These findings have direct clinical application, and suggest that modulating hsp expression may be a therapeutic target for reversal of hsp-associated detrimental cellular effects.
- Published
- 1994
- Full Text
- View/download PDF
321. Constitutive overexpression of the 27,000 dalton heat shock protein in late passage human breast cancer cells.
- Author
-
Fuqua SA, Benedix MG, Krieg S, Weng CN, Chamness GC, and Oesterreich S
- Subjects
- Adenocarcinoma genetics, Adenocarcinoma metabolism, Base Sequence, Breast Neoplasms genetics, Breast Neoplasms metabolism, Cell Division, Chromosomes, Human, Pair 3, DNA, Neoplasm genetics, DNA, Neoplasm isolation & purification, Estradiol pharmacology, Heat-Shock Proteins genetics, Hot Temperature, Humans, Molecular Sequence Data, Neoplasm Proteins genetics, Adenocarcinoma pathology, Breast Neoplasms pathology, Gene Expression Regulation, Neoplastic drug effects, Heat-Shock Proteins biosynthesis, Neoplasm Proteins biosynthesis
- Abstract
We present evidence that the mechanisms controlling induction of heat shock transcription factors (HSFs) and mRNA expression of the 27,000 molecular weight heat shock protein, hsp27, are diverse in human breast cancer cells. Heat shock accumulation of hsp27 RNA is associated with the activation of HSF in MDA-MB-231 cells. We have later passage MCF-7 breast cancer cell lines with elevated, constitutive expression of hsp27 mRNA, perhaps due to hsp27 gene amplification. Estradiol and heat shock treatment no longer affect the level of hsp27 mRNA in these cells. Heat induction of HSF is inhibited in cells overexpressing hsp27, although metal ions and amino acid analogs are still capable of activating HSF. These cells will provide a useful system for characterizing alternative pathways in HSF inhibition and activation.
- Published
- 1994
- Full Text
- View/download PDF
322. Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review.
- Author
-
Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, and Fuqua SA
- Subjects
- Animals, Gene Expression, Heat-Shock Proteins genetics, Heat-Shock Proteins metabolism, Humans, Neoplasms metabolism, Heat-Shock Proteins physiology
- Abstract
Heat shock and other environmental and pathophysiologic stresses stimulate synthesis of heat shock proteins (Hsps). These proteins enable the cell to survive and recover from stressful conditions by as yet uncompletely understood mechanisms. Hsp27 is an important small Hsp (molecular weight, 27,000) found in human cells--both cancer cells and normal cells. This protein, besides its putative role in thermotolerance, is of special clinical interest because of recent data suggesting it may also play a role in drug resistance. In adults, Hsp27 is found particularly in several cell types such as breast, uterus, cervix, placenta, skin, and platelets. Although low-molecular-weight (small) Hsps have been found to be involved in embryogenesis of Xenopus and Drosophila, they have not been detected in human fetal organs. Regulation of expression of the Hsp gene (also known as HSPB1) has been considered a paradigm of gene regulation and is actively being studied in both prokaryotes and eukaryotes. In prokaryotes, the major Hsp genes are transcriptionally regulated by positively and negatively acting transcription factors. In eukaryotes, the genes encoding Hsps contain a regulatory DNA motif (inverted repeats of the pentameric sequence nGAAn) known as the heat shock element. Hsp27 may function as a molecular chaperone and in signal transduction pathways of different cell regulators, and Hsp27 and other Hsps may be active in development of resistance to stressful conditions and agents including cytotoxic drugs. Study findings indicate that some but not all estrogen-positive breast cancers express Hsp27, and overexpression of Hsp27 has been associated with both good and poor prognosis. In endometrial carcinomas, the presence of Hsp27 is correlated with the degree of tumor differentiation as well as with the presence of estrogen and progesterone receptors. Studies suggest, however, that detection of Hsp27 should not be considered to be a method for identifying hormone-responsive tumors or detecting estrogen receptors. Hsp27 seems to be a biochemical marker of estrogenic endometrial response. In patients with cervical cancer, Hsp27 is predominantly expressed in well-differentiated and moderately differentiated squamous cell carcinomas. In addition, expression of Hsp27 seems to be a negative prognostic factor for gastric cancer. Different isoforms of Hsp27 have been found in lymphoid tissue of patients with acute lymphoblastic leukemia, and the protein has also been associated with viral infections. These aspects are summarized and discussed in the present review.
- Published
- 1993
- Full Text
- View/download PDF
323. The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines.
- Author
-
Oesterreich S, Weng CN, Qiu M, Hilsenbeck SG, Osborne CK, and Fuqua SA
- Subjects
- Base Sequence, Cell Division drug effects, Cloning, Molecular, DNA Primers, Female, Heat-Shock Proteins analysis, Humans, Molecular Sequence Data, Oligonucleotides, Antisense, Polymerase Chain Reaction, Transfection, Tumor Cells, Cultured, Biomarkers, Tumor analysis, Breast Neoplasms pathology, Doxorubicin toxicity, Drug Resistance, Heat-Shock Proteins biosynthesis
- Abstract
An emerging body of evidence suggests that the heat shock proteins (hsp) may be involved in drug resistance. When hsp are induced by elevated temperatures, resistance to doxorubicin (Dox), but not to other commonly used chemotherapeutic agents, is induced in breast cancer cells. To evaluate the role of hsp27 in this phenomenon, we have transfected MDA-MB-231 breast cancer cells, which normally express low levels of hsp27, with a full-length hsp27 construct. These hsp27-overexpressing cells now display a 3-fold elevated resistance to Dox. Anchorage-dependent proliferation and anchorage-independent growth were also increased 2-4-fold in these transfectants. We have also derived a MCF-7 breast cancer cell line with amplified endogenous hsp27 which is highly resistant to Dox. When these cells are transfected with an antisense hsp27 construct, they are rendered sensitive to Dox (3-fold) with anchorage-dependent as well as anchorage-independent growth, similarly decreased. These results suggest that hsp27 specifically confers Dox resistance in human breast cancer cells and, furthermore, that hsp27 may be involved in the regulation of cell growth.
- Published
- 1993
324. Glutathione transferase GST pi in breast tumors evaluated by three techniques.
- Author
-
Molina R, Oesterreich S, Zhou JL, Tandon AK, Clark GM, Allred DC, Townsend AJ, Moscow JA, Cowan KH, and McGuire WL
- Subjects
- Blotting, Northern, Blotting, Western, Breast enzymology, Female, Humans, Immunohistochemistry, Lymphocytes enzymology, Prognosis, Breast Neoplasms enzymology, Glutathione Transferase analysis, Isoenzymes analysis
- Abstract
The glutathione transferases are involved in intracellular detoxification reactions. One of these, GST pi, is elevated in some breast cancer cells, particularly cells selected for resistance to anticancer agents. We evaluated GST pi expression in 60 human breast tumors by three techniques, immunohistochemistry. Northern hybridization, and Western blot analysis. There was a significant positive correlation between the three methods, with complete concordance seen in 64% of the tumors. There was strong, inverse relationship between GST pi expression and steroid receptor status with all of the techniques utilized. In addition, there was a trend toward higher GST pi expression in poorly differentiated tumors, but no correlation was found between tumor GST pi content and DNA ploidy or %S-phase. GST pi expression was also detected in adjacent benign breast tissue as well as infiltrating lymphocytes; this expression may contribute to GST pi measurements using either Northern hybridization or Western blot analysis. These results suggest that immunohistochemistry is the method of choice for measuring GST pi in breast tumors.
- Published
- 1993
- Full Text
- View/download PDF
325. Cisplatin induces the small heat shock protein hsp25 and thermotolerance in Ehrlich ascites tumor cells.
- Author
-
Oesterreich S, Schunck H, Benndorf R, and Bielka H
- Subjects
- Animals, Carcinoma, Ehrlich Tumor pathology, Cell Count, Cell Cycle drug effects, Cell Survival drug effects, Electrophoresis, Polyacrylamide Gel, Flow Cytometry, Humans, Tumor Cells, Cultured, Cisplatin pharmacology, Heat-Shock Proteins biosynthesis
- Abstract
Exposure of Ehrlich ascites tumor (EAT) cells to the anticancer drug cisplatin results in an elevated abundance of three isoforms of the small heat shock protein hsp25 without inducing the general stress response as commonly observed after heat shock. The most effective cisplatin concentration (2.5 microM) is also most efficient in arresting cells in S phase suggesting a relationship between hsp25 expression and cell cycle events. Exposure to cisplatin results also in an increased thermotolerance of EAT cells.
- Published
- 1991
- Full Text
- View/download PDF
326. The expression of the growth-related 25kDa protein (p25) of Ehrlich ascites tumor cells is increased by hyperthermic treatment (heat shock).
- Author
-
Oesterreich S, Benndorf R, and Bielka H
- Subjects
- Animals, Arsenic pharmacology, Female, Hot Temperature, Mice, Mice, Inbred ICR, Molecular Chaperones, Neoplasm Proteins genetics, Phosphorylation, Protein Processing, Post-Translational, Arsenites, Carcinoma, Ehrlich Tumor metabolism, Gene Expression Regulation, Neoplastic drug effects, Heat-Shock Proteins, Neoplasm Proteins biosynthesis
- Abstract
The abundance of a 25 kDa protein (p25) and at least two phosphorylated isoforms is inversely correlated with the rate of in vivo growth of the Ehrlich ascites tumor (EAT). On the basis of cDNA sequence data, p25 shows an about 80% amino acid sequence homology to the mammalian heat shock protein hsp27 (Gaestel et al., Europ. J. Biochem. 179, 209, 1989). In this paper, the following data are presented and discussed: 1. The expression of p25 is increased by in vitro incubation of cells at elevated temperatures (41.5 degrees C-43.5 degrees C). 2. A two-step hyperthermic treatment with a recovery period at 37 degrees C results in a more elevated p25 expression than a one-step hyperthermia. Moreover, the two-step hyperthermic treatment results in thermotolerance in terms of protein biosynthesis and cell vitality. 3. Also the appearance of p25 isoforms depends on the temperature regimes. While after a one-step hyperthermia the phosphorylated isoforms p25/2 and p25/3 predominate, the unphosphorylated isoform p25/1 is more strongly expressed after a two-step hyperthermic treatment, which results also in a more increased total p25 synthesis than a one-step treatment. 4. The synthesis of p25 and its induction by hyperthermic treatment in EAT cells depends on the stage of tumor growth from which the cells were harvested. Both, the endogenous synthesis and the induction by elevated temperature are higher in cells from the exponentially growing tumor than in cells from the stationary tumor. The results are discussed with respect to correlations between regulation of tumor growth and the abundance of p25, its synthesis and induction during tumor growth.
- Published
- 1990
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.